Tirzepatide Maintenance Dose After Weight Loss

Three products carry tirzepatide, and only one of them has a maintenance dosage for weight

Tirzepatide is the molecule. What you are actually holding is a product, and the product decides whether the phrase "maintenance dose" has an approved meaning at all. This is the distinction that most pages on this question skip, and it changes the answer completely.

So if the prescription in your hand says Zepbound, the question has an answer in a document: 5 mg, 10 mg or 15 mg. If it says Mounjaro, the document you are reading was written for blood sugar, and weight maintenance sits outside what it was approved to describe. If your tirzepatide was compounded, there is no document.

What the 2026 trial tested, and what it found

Until recently the honest answer to "can I go down to a lower dose once the weight is off" was that nobody had run the trial. In May 2026 that changed. SURMOUNT-MAINTAIN was published in The Lancet: a phase 3b trial that put the step-down question to a randomised test rather than to opinion.

The design matters for reading the numbers. Everyone first spent 60 weeks on open-label tirzepatide at their maximum tolerated dose, 10 mg or 15 mg. Only then, at week 60, were 378 people randomly assigned in a 3:3:2 ratio to one of three arms for another 52 weeks. From week 84 onward, anyone who had regained more than half of what they had lost could be given rescue tirzepatide, which is why the rescue column below is as informative as the weight column.

Read the three rows as a sequence rather than a winner. Stepping down to 5 mg did not hold the line the way staying put did: the gap between those two arms is 5.3 percentage points of body weight, and three times as many people in the 5 mg arm needed rescue. But stepping down was nothing like stopping. Two thirds of the placebo arm regained at least half of what they had lost within the year, against a quarter at 5 mg.

The trial authors put it this way in their own conclusion: reducing to 5 mg tirzepatide "might provide a valuable alternative to discontinuation, although individuals' treatment response might vary." That sentence is doing real work. It is a statement about a group average, offered as an alternative to stopping, not as an equal to continuing.

Four limits worth carrying into the appointment

• The step-down tested was to 5 mg, and nothing else. No arm went from 15 mg to 10 mg, and no arm went to a longer interval between injections. Those are different questions with no trial behind them.
• Everyone had already reached a maximum tolerated dose. The results describe people who got to 10 mg or 15 mg and stayed there 60 weeks. If you have been maintaining on 5 mg all along, this trial did not study you.
• It was conducted at 20 sites in the USA and funded by Eli Lilly, the manufacturer. That is normal for a registration-adjacent trial and it is also a fact a reader should have.
• Rescue therapy was available from week 84. The headline percentages use an estimand that assumes rescued participants gained no further benefit from their assigned arm, which is why the rescue counts belong next to the weight figures rather than in a footnote.

If your prescription says Mounjaro

Mounjaro and Zepbound are the same molecule from the same manufacturer at the same six strengths. They are not the same approval. The Mounjaro label is written for type 2 diabetes: its escalation instruction is to increase in 2.5 mg increments after at least 4 weeks "if additional glycemic control is needed", and it names a maximum of 15 mg in adults but no maintenance dosage at all.

That is not a loophole or a technicality you can read past. It means the question "what is my maintenance dose after weight loss" has no labelled answer for Mounjaro, and anyone who gives you one is extrapolating from the Zepbound label or from the trials. Your prescriber can make that judgement with your blood sugar, your weight and your tolerance in front of them. A web page cannot.

If your tirzepatide is compounded

The FDA's position is short: "compounded drugs are not FDA approved. This means the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed." There is no approved label, so there is no approved maintenance dosage, and there is no regulatory guarantee that the concentration in this vial matches the concentration in the last one.

The practical consequence is about record keeping rather than argument. When the strength printed on the vial is the only thing standing between you and a dosing error, the written record of what you actually drew and when becomes the primary document, not a convenience. Keep it, and take it with you.

What to bring to the appointment where this gets decided

The maintenance decision is not a number you look up. It is a conversation your prescriber runs on five inputs, and every one of them is something you hold rather than something they can see.

1. The dose you were on when the weight stopped falling, and roughly when it stopped. Plateau at a dose is a different situation from plateau at goal.
2. A weight trend over at least eight weeks, not a single reading. Week-to-week noise is larger than the signal this decision turns on.
3. Every week you skipped, split or injected late. A missed week looks exactly like a dose that stopped working.
4. Gastrointestinal symptoms week by week, set against the dose that was actually in you that week. Tolerability is the one thing the Zepbound label explicitly tells the prescriber to weigh when selecting a maintenance dosage, and it is the only labelled reason given for moving to a lower one.
5. Which product and which presentation you actually hold. Zepbound or Mounjaro, pen or vial or KwikPen, brand or compounded. As the table above shows, this is the input that decides which rules apply.

Four of those five are a dose history. If yours lives in your memory, it will be thinner at the appointment than it feels now.

Frequently asked questions

Can I lower my tirzepatide dose once I reach my goal weight?

That is a prescriber decision, and as of 2026 it has randomised evidence behind it rather than only opinion. In SURMOUNT-MAINTAIN, people who reduced from their maximum tolerated dose to 5 mg were at -16.6% of baseline body weight at week 112, against -21.9% for those who stayed at the maximum tolerated dose and -9.9% for those switched to placebo. Stepping down held less than staying put and far more than stopping.

What is the lowest maintenance dose of tirzepatide?

For Zepbound, 5 mg once weekly is the lowest of the three dosages the label names as a maintenance dosage for weight reduction. The 2.5 mg starting dosage is excluded in writing: the label states it is for treatment initiation and is not approved as a maintenance dosage.

Is the Mounjaro maintenance dose the same as the Zepbound maintenance dose?

No, because the Mounjaro label does not contain one. Mounjaro is approved for type 2 diabetes and for cardiovascular risk reduction in type 2 diabetes. Its dosing section describes increasing in 2.5 mg increments if additional glycemic control is needed, up to a maximum of 15 mg in adults, and it never names a maintenance dosage. The two products share a molecule and six strengths, not an indication.

How much weight do people regain if they stop tirzepatide?

Two trials give figures. In SURMOUNT-4, the group switched to placebo after 36 weeks regained a mean of 14.0% of body weight over the following 52 weeks while those who continued lost a further 5.5%. In SURMOUNT-MAINTAIN, 67% of the placebo arm regained at least half of what they had lost and received rescue tirzepatide, against 8% of those who continued at the maximum tolerated dose.

Is there a maintenance dose for compounded tirzepatide?

There is no approved one, because there is no approved label. The FDA states that compounded drugs are not FDA approved and that the agency does not review them for safety, effectiveness or quality before marketing. Any dosing plan for a compounded product comes from the prescriber who wrote it, and the strength printed on the vial is the only reference point you have.

How long should a new maintenance dose be given before judging it?

The Zepbound label allows an increase only after at least 4 weeks on the current dose, so 4 weeks is the smallest unit the document works in. In practice a plateau judgement needs longer than that, because week-to-week weight variation is larger than the trend you are trying to read.

Related reading

• Zepbound maintenance dose after goal weight, for the brand-specific version of this question and what the label says about 7.5 mg
• GLP-1 maintenance dose after weight loss, for every approved weight-management label side by side
• Why increase the Zepbound dose?, for what each step up buys and what it costs
• Zepbound 7.5 mg weight loss, on the one strength with no trial arm behind it
• Long-term side effects of Zepbound, for how far the safety evidence runs on staying on it
• Tracking tirzepatide injections, for keeping the dose history this decision runs on
• Cheapest tirzepatide without insurance, self-pay prices by dose and the 45-day refill condition
• How to get Zepbound covered by insurance, the appeal deadlines that apply to a continuation denial

Sources

• ZEPBOUND (tirzepatide) US prescribing information, Eli Lilly and Company. Section 2.1 for the escalation schedule and the 2.5 mg exclusion, section 2.2 for the three recommended maintenance dosages and the 15 mg maximum, section 1 for the weight reduction and obstructive sleep apnea indications.
• MOUNJARO (tirzepatide) US prescribing information, Eli Lilly and Company. Section 1 for the type 2 diabetes and cardiovascular indications, section 2.1 for the glycemic escalation instruction and the 15 mg maximum. Checked for a maintenance dosage section, which it does not contain.
• Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2026;407(10545):2305-2318. PMID 42119587. DOI 10.1016/S0140-6736(26)00656-2. Trial registration NCT06047548. Source of the week 112 figures, the randomisation ratio, the rescue therapy counts and the authors' conclusion.
• Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. PMID 38078870. Source of the 14.0% regain and 5.5% further reduction from week 36 to week 88.
• FDA's concerns with unapproved GLP-1 drugs used for weight loss, US Food and Drug Administration, for the statement that compounded drugs are not FDA approved and are not reviewed for safety, effectiveness or quality.
• ZEPBOUND label on DailyMed and MOUNJARO label on DailyMed, US National Library of Medicine, for independently hosted copies of both labels.

Jabby is free on the App Store and keeps every dose, date, injection site and side effect on one timeline, so the eight weeks of trend your prescriber asks for is a record rather than a recollection.